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DOI 10.1016/j.ccr.2012.04.026SUMMARYThe tumor suppressor cylindromatosis (CYLD) inhibits the NFkB and mitogen-activated protein kinase
(MAPK) activation pathways by deubiquitinating upstream regulatory factors. Here we show that liver-
specific disruption of CYLD triggers hepatocyte cell death in the periportal area via spontaneous and chronic
activation of TGF-b activated kinase 1 (TAK1) and c-Jun N-terminal kinase (JNK). This is followed by hepatic
stellate cell and Kupffer cell activation, which promotes progressive fibrosis, inflammation, tumor necrosis
factor (TNF) production, and expansion of hepatocyte apoptosis toward the central veins. At later stages,
compensatory proliferation results in the development of cancer foci featuring re-expression of oncofetal
hepatic and stem cell-specific genes. The results demonstrate that, in the liver, CYLD acts as an important
regulator of hepatocyte homeostasis, protecting cells from spontaneous apoptosis by preventing uncon-
trolled TAK1 and JNK activation.INTRODUCTION
The nuclear factor (NF)-kB signaling pathway regulates multiple
physiological and pathological processes, including immune
responses and carcinogenesis (Vallabhapurapu and Karin,
2009). The principal regulatory step of NFkB-mediated signal
transduction is the activation of IkB kinase (IKK), which phos-
phorylates members of the IkB family of inhibitory proteins that
keep NFkB transcription factors inactive in the cytoplasm. The
IKK complex consists of two catalytic subunits (IKK1 and IKK2)
and the regulatory subunit (NEMO/IKKg). It is interesting and
pertinent to function that IKK activation by different receptor
signals involves conjugation of K63-linked ubiquitin chains to
several upstream regulatory components of the signaling
cascade. These include the TNF receptor associated factors
TRAF2 and TRAF6, the TGFb-activated kinase TAK1, the
receptor interacting protein RIP1 and NEMO (Sun, 2008; Chen,
2005). K63-linked poly-ubiquitin chains serve as interactionSignificance
Previous studies have revealed protumorigenic effects of gene
IKKb, suggesting that the NFkB signaling pathway plays a ce
(HCC). The results presented here provide further insights into
to expectations, we found that liver-specific inactivation of CY
gers a multistep mechanism that mimics the major hallmarks o
The data suggest that controlling TAK1-induced downstream s
ical for the maintenance of physiological liver homeostasis, as
pathway is cancer.
738 Cancer Cell 21, 738–750, June 12, 2012 ª2012 Elsevier Inc.surfaces to facilitate the formation of stable TNFR1 core
signaling complexes and/or act as modulators of the enzymatic
activities of the modified factors (Chen, 2005; Sun, 2010). For
example, poly-ubiquitination of TAK1 is required for its activity
to phosphorylate IKK1 and IKK2 in their activation loops and
trigger IkBa phosphorylation (Rinco´n and Davis, 2009; Sun,
2010).
The recent finding that K63-linked ubiquitination is a reversible
reaction provides a strong indication that this modification
represents an important layer of regulation in the process. The
major enzyme that removes K63-linked polyubiquitin chains
from NFkB pathway effectors is the cylindromatosis tumor
suppressor CYLD (Trompouki et al., 2003; Brummelkamp
et al., 2003; Kovalenko et al., 2003; Wright et al., 2007). Overex-
pression of CYLD in mammalian cells results in deubiquitination
of NEMO and several upstream regulators like TRAF2, TRAF6, or
TAK1 (Trompouki et al., 2003; Brummelkamp et al., 2003; Kova-
lenko et al., 2003; Yoshida et al., 2005). In addition, knockdowntic ablation of TAK1, NFkB essential modulator (NEMO), and
ntral role in the pathogenesis of hepatocellular carcinoma
the mechanisms that link inflammation to cancer. In contrast
LD leads to the development of HCC. CYLD deficiency trig-
f human HCC: hepatocyte death, inflammation, and fibrosis.
ignaling cascades by the enzymatic activity of CYLD is crit-
the final outcome of either inactivation or activation of the
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CYLD Inactivation in Liveror knockout of CYLD in different cell types leads to increased
ubiquitination of these factors (Reiley et al., 2005; Zhang et al.,
2006; Reiley et al., 2007). Together, these findings have estab-
lished the view that CYLD is primarily a negative regulator of
NFkB signaling.
CYLDwas initially identified as a genemutated in familial cylin-
dromatosis that predisposes patients to the development of skin
appendage tumors (Bignell et al., 2000). The broad role of CYLD
in the regulation of cell survival and proliferation is highlighted by
the downregulation of CYLD expression in several other types
of human cancer, including colon cancer, lung cancer, multiple
myeloma, and hepatocellular carcinoma (Zhong et al., 2007; An-
nunziata et al., 2007; Keats et al., 2007; Hellerbrand et al., 2007).
Hepatocellular carcinoma (HCC) is the most common type of
liver cancer, which in most cases develops in conjunction with
chronic hepatitis or cirrhosis. Previous studies have revealed
a major role of the NFkB signaling pathway in the mechanisms
that link chronic inflammation to the pathogenesis of HCC
(Maeda et al., 2005; Luedde et al., 2007; Bettermann et al.,
2010; Luedde and Schwabe, 2011). Impediment of NFkB activa-
tion by disruption of IKKb in the liver sensitized mice to diethylni-
trosamine-induced hepatocarcinogenesis, while its deletion in
both hepatocytes and Kupffer cells had the opposite effect
(Maeda et al., 2005). Similarly, hepatocyte specific deletion of
NEMO or TAK1 in mice resulted in spontaneous development
of hepatocellular carcinoma (Luedde et al., 2007; Inokuchi
et al., 2010; Bettermann et al., 2010). As NFkB in most cancer
types is activated to provide important survival signals that
prevent apoptosis, the above, unexpected findings pointed to
the operation of a more complex process in inflammation-medi-
ated hepatocarcinogenesis, in which mediators of the NFkB
activation pathway have tumor suppressor roles (Luedde and
Schwabe, 2011).
Because TAK1 and NEMO are subject to regulation by CYLD-
mediated deubiquitination, we investigated the potential role of
CYLD in liver cancer.
RESULTS
SpontaneousHepatocyte Apoptosis and Liver Fibrosis in
CYLDLD/D Mice
To study the role of CYLD in the liver, we generatedmice carrying
liver-specific homozygous deletion of CYLD exon 9 (designated
CYLDLD/D), by crossing mice carrying CYLD with floxed exon 9
(Trompouki et al., 2009) with ALFP-Cre transgenic mice (Kellen-
donk et al., 2000). Exon 9 deletion results in the expression of
a deubiquitinase-deficient form of CYLD that mimics oncogenic
mutations described in humans (Trompouki et al., 2009). Poly-
merase chain reaction (PCR) analysis of hepatocytes from
newborn mice confirmed that excision of exon 9 was complete
during embryonic life (data not shown). In adult stages,
CYLDLD/D mice display hepatomegaly and perceptible stiffness
(Figure 1A; Table S1 available online). Western blot analyses
and immunostainings using an antibody recognizing the
C-terminal epitope of CYLD revealed loss of detectable signals
in all hepatocytes, but not in biliary epithelial cells and other
smaller non-hepatocyte cells (Figures 1A and 1B), suggesting
that ALFP-Cre-driven excision of CYLD exon 9 in embryonic
life is hepatocyte-specific and occurs after hepatoblasts havedifferentiated into hepatocytes. Interestingly, CYLD exhibits
a partially zonal expression pattern in wild-type livers, with higher
levels of expression in periportal hepatocytes and reduced levels
in hepatocytes surrounding the central veins (Figure 1B). Hema-
toxylin eosin staining of CYLDLD/D liver sections revealed disor-
ganized regions around the portal veins containing cells with
smaller nuclei as early as postnatal day 35 (P35). At later stages
of postnatal development (P45 to P120), the number of these
cells was dramatically increased, resulting in a staining pattern
that highly resembles fibrotic livers (Figure 1C). Indeed, we could
detect fibrillar collagen deposition by Sirius red staining initially
around portal veins, which was gradually enhanced at later
time points, resulting in a massively fibrotic liver at postnatal
day 60 (P60) and postnatal day 120 (P120) (Figures 1D and
1E). This correlated with the appearance and expansion of
activated hepatic stellate cells (HSCs) visualized by a smooth
muscle actin (aSMA) staining (Figure S1A).
Liver damage and associated hepatocyte death is a prerequi-
site for stellate cell activation. In line with this, TUNEL assays
detected substantial cell death around the portal veins of
CYLDLD/D livers, as early as P25 (Figures 2A and 2B). The number
of TUNEL positive apoptotic cells was greatly increased during
the period between P25 and P120, which correlated with
increasing levels of cleaved caspase 3 and parallel elevation of
serum ALT levels (Figures 2A–2D). These results also indicate
that apoptosis is the main pathway of cell death in CYLDLD/D
livers. Supporting this notion, only a negligible increase in the
levels of the necrosis marker RIP3 protein was detected in
CYLDLD/D livers (Figure S1B).
To understand the mechanism by which CYLD inactivation
leads to cell death, we first analyzed the activation of Jun
N-terminal kinase (JNK), which is known to trigger apoptosis in
several cell types when its activity is sustained for long periods
of time (Kamata et al., 2005; Schwabe andBrenner, 2006). Spon-
taneous activation of JNK was observed in CYLDLD/D livers from
P25 day onward (Figure 2E). The enhanced intensity of the phos-
pho-JNK signal in western blots of extracts from P35, P45, and
P60 CYLDLD/D livers correlated with an increased number of
phospho-JNK positive hepatocytes detected by immunohisto-
chemistry (Figure 2F). Double staining with HNF4 antibody
revealed that more than 90% of p-JNK positive cells were hepa-
tocytes at P25 and P35 days, while at later time points hepato-
cytes corresponded to about two-thirds of the pJNK positive
cell population (Figure 2G). Importantly, phospho-JNK positive
hepatocytes were initially observed only around portal veins,
while at later time points, cells in the surrounding area toward
the central veins also stained positively (Figure 2F). Activation
of JNK was confirmed by a similar time-dependent induction
of c-JUN phosphorylation (Figure 2H) and by the induction of
expression of downstream target genes DR5 and PUMA
(Figure S2A).
Further evidence for the role of sustained JNK activation in
hepatocyte death in CYLDLD/D livers was provided by experi-
ments using the JNK inhibitor compound SP600125. Apoptosis
and fibrosis were dramatically reduced in mice that were treated
twice daily with SP600125 between P30 and P60 compared to
those treated with vehicle only (Figures S2B–S2F). In addition,
we could detect phosphorylated JNK in primary hepatocytes





Figure 1. Loss of CYLD Causes Hepatomegaly, Histological Alterations, and Progressive Fibrosis in the Liver
(A) Western blot analysis of whole liver protein extracts from 45-day-old (P45)CYLDlox/lox/ALFP-Cre (CYLDLD/D) mice and control littermates (WT) using antibodies
recognizing the C-terminal part of CYLD or TFIIB. Lower panel: Macroscopic appearance of P60 CYLDLD/D and WT livers.
(B) Representative immunohistological staining of liver sections from 45-day-old CYLDLD/D mice and control littermates (WT) with aCYLD antibody.
(C) Hematoxylin and Eosin staining of liver sections from postnatal 25-day-old (P25), 35-day-old (P35), 45-day-old (P45), 60-day-old (P60), and 120-day-old
(P120) CYLDLD/D mice and control littermates (WT).
(D) Sirius Red staining of liver sections from mice indicated as in (C).
(E) Quantitation of Sirius red positive areas. Bars represent percentages of Sirius red positive areas compared to total areas and standard errors of the mean
(SEM) from data obtained by examination of nine whole sections from three different animals.
See also Figure S1 and Table S1.
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CYLD Inactivation in Liverwith TNFa (Figure S2G). In wild-type hepatocytes, TNFa-medi-
ated JNK activation was transient but could be prolonged by
priming with cycloheximide (CHX). In contrast, prolonged JNK740 Cancer Cell 21, 738–750, June 12, 2012 ª2012 Elsevier Inc.activation without CHX was readily detected in CYLDLD/D hepa-
tocytes (Figure S2I). The length of JNK activation correlated
with the extent of cell death mediated by TNFa: significant
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CYLD Inactivation in LiverTNFa-induced cell death could be observed in CYLDLD/D hepa-
tocytes, without concomitant CHX treatment, while in the case
of wild-type cells, it was detected only after CHX priming
(Figure S2H). Importantly, inhibition of JNK activation by
SP600125 greatly prevented death in both cases (Figure S2H).
Collectively, the above results indicate that CYLD inactivation
causes spontaneous hepatocyte death via prolonged activation
of JNK. In turn, hepatocyte damage triggers the activation and
proliferation of hepatic stellate cells, which produce ECM
proteins generating progressively expanding fibrotic lesions.
Constitutive Hyperactivation of TAK1 in CYLDLD/D Mice
The mechanism of prolonged JNK activation-mediated
apoptosis in our mouse model is likely to involve upstream sig-
naling enzymes, which are direct enzymatic targets of CYLD.
In agreement with this, western blot analysis using phospho-
specific TAK1 antibodies detected spontaneous activation of
TAK1 in CYLDLD/D livers and in primary hepatocyte extracts
(Figures 3A and S3A). Phospho-TAK1 induction in CYLDLD/D
livers positively correlated with increased K63-linked ubiquitina-
tion of endogenous TAK1 (Figure 3C). The amount of phos-
phorylated TAK1 was further elevated upon LPS treatment
(Figure 3B). Importantly, high phospho-TAK1 levels were sus-
tained for at least 2 hr following LPS treatment inCYLDLD/D livers,
as opposed to wild-type livers in which TAK1 phosphorylation
declined after 1 hr (Figure 3B).
To obtain direct evidence into the role of TAK1 hyperactivation
in the phenotype of CYLDLD/D mice, we generated liver-specific
CYLDLD/D/TAK1LD/D double knockout mice. In agreement with
previous reports (Bettermann et al., 2010; Inokuchi et al.,
2010), TAK1LD/Dmice developed early liver tumors as evidenced
by macroscopically visible nodules in the liver, and, by the
observation of cellular dysplasia, lost portal tracts and the
appearance of cells with enlarged and hyperchromatic nuclei
(Figures 3D and 3E). Serum ALT levels were dramatically
induced, reaching levels that were four times higher than those
detected in CYLDLD/D mice (Figure 3K). TAK1-deficient mice
also displayed liver fibrosis and apoptosis, albeit at much
lower levels compared to those observed in CYLDLD/D mice
(Figures 3E–3I).
The phenotype of 2-month-old CYLDLD/D/TAK1LD/D double
knockout mice greatly differed from that observed in
CYLDLD/D mice and very much resembled that of TAK1LD/D
mice. Double knockout mice did not develop hepatomegaly,
as was seen in CYLDLD/D mice. Instead, cancerous nodules
were observed, as was seen in TAK1LD/D mice. Hepatic
fibrosis and apoptosis and pJNK levels were dramatically
reduced in double knockout mice while serum ALT levels
were increased, reaching a level comparable to TAK1LD/D
mice (Figures 3D–3K and Table S1). Importantly, the few
apoptotic cells observed in different fields were scattered
throughout the liver parenchyma in the CYLDLD/D/TAK1LD/D
double knockout mice as opposed to their periportal zonation
in CYLDLD/D mice (Figures 3G and 2A). Likewise, the relatively
minor fibrotic lesions in the CYLDLD/D/TAK1LD/D double
knockout mice appeared around both central and portal areas,
a distribution that clearly differed from the strict periportal
pattern observed in CYLDLD/D mice (Figure 3E). These quanti-
tative and qualitative differences suggest that induction of celldeath is achieved via different mechanisms in TAK1 and
CYLD-deficient mice. Nevertheless, we can conclude that
TAK1 activation is required for the initiation of periportal cell
death and fibrosis in CYLDLD/D mice, as these early phenotypic
changes were not observed in CYLDLD/D/TAK1LD/D double
knockout mice.
Constitutively active TAK1 can fully explain the observed long-
term activation of JNK in CYLDLD/D hepatocytes, as it acts
upstream of JNK. However, other mechanisms, including reac-
tive oxygen species (ROS) accumulation, may also contribute
to it (Kamata et al., 2005; He et al., 2010). To explore this possi-
bility, ROS production was evaluated by staining liver sections
with the H2O2-sensitive fluorescent dye CM-H2DCFDA. As
shown in Figure S3B, a few positive signals can be specifically
detected in CYLDLD/D liver sections as early as P35, which
greatly expand at P60 and 1 year of age. Similar to previous find-
ings in IKKb-deficient mice (He et al., 2010), ROS production
resulted in the activation of STAT3 in CYLDLD/D mice (Fig-
ure S4A). No significant differences were detected in activated
p38 levels, which also acts downstream of TAK1 (Figure S4B).
Thus, we conclude that, apart from constitutively active TAK1,
the accumulation of ROS, especially at later stages, can play
a significant role in sustaining JNK activation and the consequent
hepatocyte death.
Expansion of Cell Death in CYLDLD/D Livers Requires
TNF Receptor Signaling
As described above, initially (at P25) only few apoptotic cells
could be detected in the periportal region of CYLDLD/D livers,
whose number gradually increased over time and expanded
toward central veins. A possible explanation for this phenom-
enon could be that the initial, periportally restricted sponta-
neous hepatocyte injury could trigger inflammation and the
consequent inflammation-mediated death receptor signaling
may induce more widespread hepatocyte apoptosis. To
explore this hypothesis, we first analyzed Kupffer cell activation
using the F4/80 and CD68 macrophage markers. As shown in
Figure 4A and Figure S4C, we could detect an increasing
number of F4/80 and CD68 positive cells in CYLDLD/D livers
from day P35 and onward. Using the CD45 marker, we also
observed the appearance and expansion of other inflammatory
cells in a similar time-dependent manner (Figure 4B). A parallel
increase in hepatic TNFa mRNA levels was detected (Fig-
ure 4C). NFkB activation was evaluated by electrophoretic
mobility shift assays and immunostaining. After LPS treatment,
activated NFkB signal in CYLDLD/D livers occurred earlier than
in wild-type livers, suggesting that loss of CYLD sensitizes
hepatocytes to LPS-mediated NFkB activation (Figure 4D).
TNFa-mediated activation of NFkB was more pronounced in
CYLDLD/D primary hepatocytes, but unlike JNK activation, the
induction of NFkB was transient, displaying a similar time-
dependent decline in wild-type and CYLD-deficient cells
(Figure S4D).
Unexpectedly, the earliest time point when activation of NFkB
could be detected in vivo was only at P45 (Figure 4D). This coin-
cides with the timing of first detection of elevated levels of
hepatic TNFa mRNA (Figure 4C). Potential technical concerns
in the sensitivity of the assay were eliminated by examining the







Figure 2. Liver-Specific Ablation of CYLD Leads to Spontaneous and Persistent Activation of JNK and Hepatocyte Apoptosis
(A) TUNEL staining of apoptotic cells in sections from livers of CYLDLD/D mice and control littermates (WT) between 25 and 120 days.
(B) Quantitation of TUNEL positive cells. Bars represent mean numbers of TUNEL positive cells per high power field (HPF) and SEM in 10 HPFs of three different
animals.
(C)Western blot analysis of extracts from individual livers of 25- to 60-day-oldCYLDLD/Dmice and control littermates (WT) using an antibody specifically detecting
cleaved caspase 3 (upper panel) or TFIIB (lower panel).
(D) Serum alanine aminotransferase levels (ALT) in 25- to 120-day-old CYLDLD/D mice and control littermates (WT). Bars represent mean values and SEM from
samples of five individual mice.
(E) Western blot analysis of extracts from individual livers using antibody recognizing the Thr183/Tyr185-phosphorylated form of JNK (p-JNK) or total
JNK (JNK).
(F) Immunohistological staining of liver sections from mice indicated as in (B) using phospho-JNK and HNF4 antibody.
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C Figure 3. Spontaneous Activation of TAK1
Is Required for Apoptosis and Fibrosis in
Liver-Specific CYLD-Deficient Mice
(A) Western blot analysis of extracts from indi-
vidual livers of P25 to P60 CYLDLD/D mice and
control littermates (WT) using an antibody specif-
ically detecting the Thr184/187-phosphorylated
form of TAK1 (p-TAK1) and total TAK1 (TAK1).
(B) Western blot analysis of extracts from the livers
P60 CYLDLD/D mice and control littermates (WT)
prepared at the indicated time points after intra-
peritoneal injection with 5 mg/kg LPS.
(C) Detection of K63-linked polyubiquitination of
TAK1 in liver extracts from animals indicated as in
(A) by immunoprecipitation with aTAK1 antibody
followed by western blot analysis using aK63-Ub
antibody. The amounts of total TAK1 in the
immunoprecipitates were detected by western
blot using aTAK1 antibody (bottom panel).
(D) Macroscopic appearance of 60-day-old
TAK1lox/lox/ALFP-Cre (TAK1LD/D), CYLDLD/D,
and CYLDlox/lox/TAK1lox/lox/ALFP-Cre (CYLDLD/D /
TAK1LD/D) livers. The number of tumor foci, tumor
sizes, and areas were evaluated in five mice at
2 months of age.
(E) Hematoxylin-eosin and Sirius red staining of
liver sections from P60 CYLDLD/D, CYLDLD/D/
TAK1LD/D, and TAK1LD/D mice.
(F) Quantitation of Sirius red positive areas.
(G and H) TUNEL assays in liver sections and
quantitations in P60 mice indicated as in (E).
(I) Western blot assay detecting cleaved caspase 3
in P60 mice indicated as in (E).
(J) Western blot assay detecting p-JNK in P60
mice indicated as in (E).
(K) Serum ALT levels in mice indicated as in (E).
Bars represent mean values and SEM from
samples of five individual mice.
See also Figure S3.
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CYLD Inactivation in Liver(cFLIP) and by immunohistochemical assays detecting the distri-
bution of NFkB between the nucleus and the cytoplasm.
Increased cFLIP protein levels were detected in P45 and P60
CYLDLD/D livers, but not at earlier time points (Figure S4E).
Despite examining a large number of fields, we could not identify
cells with nuclear NFkB staining at P25 and P35 (Figure 4E and
data not shown). In contrast, our immunohistochemical assays
indicate that the source of the observed NFkB DNA binding
signal at P60 must be, at least in part, hepatocytes, as we de-(G) Quantitation of pJNK positive hepatocytes. Bars represent mean numbers per HPF and SEM of JNK pos
non-hepatic cells (JNK+/HNF4-) in 10 HPFs of three different mice.
(H) Western blot analysis of extracts from individual livers using antibody recognizing Ser63-phosphorylated
See also Figure S2.
Cancer Cell 21, 738–7tected nuclear localization of NFkB-p65
in several hepatocytes of P60 CYLDLD/D
livers (Figure 4E).
Compelling evidence for the require-
ment of TNF receptor signaling in theexpansion of hepatocyte apoptosis was provided by the data
obtained with CYLDLD/D/TNFR1/ double knockout mice.
Genetic ablation of p55-TNFR1 in CYLD-deficient mice pre-
vented the development of hepatomegaly (Figure 5A and Table
S1). Sirius red and TUNEL staining was limited to the periportal
area in 2-month-old mice, without expansion to the neighboring
areas (Figures 5B–5E). In agreement with the reduced number of
TUNEL positive cells, we detected smaller amounts of cleaved
caspase 3 and serum alanine transaminase (ALT) levels initive hepatocytes (JNK+/HNF4+) and JNK positive
form of c-JUN (p-JUN) or total JUN (JUN).





Figure 4. Spontaneous and Progressive Kupffer Cell Activation, Inflammatory Cell Infiltration, TNF Production, and NFkB Activation in the
Livers of CYLD-Deficient Mice
(A and B) Immunohistological staining of liver sections from P25 to P60 CYLDLD/D mice and control littermates (WT) with F4/80 and CD45 antibody.
(C) TNFa mRNA levels from RT-qPCR assays in the livers of mice as indicated in (A). Bars represent mean values of TNFa mRNA levels normalized to glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) mRNA and SEM from samples of four individual mice.
(D) Electrophoretic mobility shift assays were performed using radioactive double stranded oligonucleotide containing NFkB binding site sequence and extracts
from the livers of indicated mice. Where indicated, mice were injected intraperitoneally with 5 mg/kg LPS.
(E) Representative immunohistological staining detects cytoplasmic and nuclear NFkB-p65 in P35 and P60 CYLDLD/D mice and control littermate (WT).
See also Figure S4.
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CYLD Inactivation in LiverCYLDLD/D/TNFR1/ mice compared to CYLDLD/Dmice (Figures
5F and 5G).
These data suggest that after the initial spontaneous
apoptosis of periportal hepatocytes, inflammatory cells are re-744 Cancer Cell 21, 738–750, June 12, 2012 ª2012 Elsevier Inc.cruited to the liver, in parallel with proliferation and activation
of resident Kupffer cells. They produce inflammatory cytokines,
such as TNFa, which, in turn, induce apoptosis in neighboring






Figure 5. TNF Receptor 1 Is Required for
the Expansion of Apoptosis and Fibrosis in
Liver-Specific CYLD-Deficient Mice
(A) Macroscopic appearance of P60 CYLDLD/D
and CYLDLD/D /TNFR1/ livers.
(B) Hematoxylin-eosin and Sirius red staining of
liver sections from P60 CYLDLD/D, CYLDLD/D/
TNFR1/, and TNFR1/ livers mice.
(C) Quantitation of Sirius red positive areas.
(D and E) TUNEL assays and quantitation of P60
livers indicated as in (B).
(F) Western blot analysis of extracts from indi-
vidual livers of P60 mice indicated as in (B) using
an antibody specifically detecting cleaved cas-
pase 3 (upper panel) or TFIIB (lower panel).
(G) Serum ALT levels in mice indicated as in (B).
Bars represent mean values and SEM from
samples of 5 individual mice.
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CYLDLD/D Mice
Examination of 12-month-old CYLDLD/D livers revealed the pres-
ence of numerous cancerous foci of different sizes (Figure 6A).
Microscopically, we could detect several histopathological
features of hepatocellular carcinoma, including nuclear atypia,
frequent pleomorphism, irregular trabeculae, obliteration of
portal tracts, mitotic figures, and the presence of cells with
increased eosinophilic inclusions or cytoplasmic clearance
(Figure 6B).
Genome-wide comparative genomic hybridization (CGH)
analysis revealed a large number of amplifications and deletions
ranging from0.62MB to 14.8MB in all chromosomes (Figure S5).Cancer Cell 21, 738–7Notably, several of the amplifications or
deletions were detected in foci derived
from different animals, pointing to the
existence of common signatures gener-
ated by CYLD-dependent signals that
affect chromosomal integrity. In addition,
the expression of several known onco-
genes and tumor suppressor genes was
upregulated (38 genes) or downregulated
(9 genes) in 1-year-old CYLDLD/D livers
(Table S2).
Malignant tumor formation was further
confirmed by the detection of prolifer-
ating cells using BrdU and Ki67 staining
and by the detection of increased Cyclin
D1 expression inCYLDLD/D livers (Figures
6D and 7A). Excessive inflammation and
liver damage in CYLDLD/D mice was also
evident from the massive infiltration of
CD45 positive cells and the highly
elevated serum ALT levels (Figures 6C
and 6D). Importantly, we observed posi-
tive staining and/or increased RNA levels
of several oncofetal HCC marker genes,
such as alpha-fetoprotein (AFP), H19,
insulin-like growth factor 2 (IGF2), as
well as hepatic stem cell marker geneslike glypican 3 (GPC-3), CD133, or the oval cell-specific A6
(Figures 6D, 7A, and 7B). Interestingly, we could detect activa-
tion ofNANOG, SOX2, and KLF4, which are involved in themain-
tenance of pluripotency of embryonic stem cells (Figure 7C).
Within the tumor area, about 25% of HNF4 positive cells stained
positively for SOX2 and all SOX2 positive cells co-stained for
HNF4 (Figure 7D).
The mRNA and protein levels of b-catenin were signifi-
cantly increased in CYLDLD/D livers. However, the observed
increase was due to the accumulation of non-hepatic cells with
elevated b-catenin expression (Figure S6). Of note, in both
wild-type and CYLDLD/D livers, we could detect only




Figure 6. Spontaneous, Late-Onset Devel-
opment of Hepatocellular Carcinoma in
Liver-Specific CYLD-Deficient Mice
(A) Macroscopic appearance of 1-year-old
CYLDLD/D mice and their control littermate (WT).
The numbers of tumor foci, tumor sizes, and areas
were evaluated in 11 mice at 1 year of age.
(B) Representative hematoxylin-eosin staining of
liver sections of 1-year-old CYLDLD/D mice and
their control littermate (WT).
(C) Serum ALT levels in 1-year-old mice. Bars
represent mean values and SEM from samples of
five individual mice.
(D) Representative immunohistochemical staining
of liver sections of 1-year-old CYLDLD/D mice and
control littermates (WT) with combinations of
antibodies indicated at the bottom of the images.
See also Figure S5.
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tumorigenesis.
The expression of other cancer marker genes, including
connective tissue growth factor (CTGF) and EpCAM, was
also increased in CYLDLD/D livers (Figures 6D and 7A). Counter-
staining of the sections with the hepatocyte markers HNF4
or albumin showed that all of the AFP positive cells and a
large number of Ki-67, EpCAM, or A6 positive cells are hepato-
cytes. Positive staining for EpCAM and A6, which besides
cancerous hepatocytes also mark biliary epithelial cells in
normal liver, was observed in a significant number of non-
hepatic cells. These cells may correspond to proliferating
cholangiocytes (Figure 6D). The observed mixed pattern of
EpCAM and A6 expression, together with the expression of
oncofetal and stem cell marker genes, suggests that the
tumors developing in CYLDLD/D livers resemble highly aggres-746 Cancer Cell 21, 738–750, June 12, 2012 ª2012 Elsevier Inc.sive hepatocellular carcinoma, possibly
combined with cholangiocarcinoma.
DISCUSSION
Previous studies have established that
CYLD is a negative regulator of NFkB
activation (Trompouki et al., 2003; Brum-
melkamp et al., 2003; Kovalenko et al.,
2003). Because NFkB is a key regulator
of cell survival and plays a protective
role against programmed hepatocyte
death (Ghosh and Karin, 2002; Pikarsky
et al., 2004; Schwabe and Brenner,
2006), its inhibition was assumed to
contribute to the known tumor sup-
pressor function of CYLD, at least in
some malignancies (Espinosa et al.,
2010; Sun, 2010). Contrasting this view,
the results of the present study demon-
strate that loss of CYLD in hepatocytes
causes spontaneous apoptosis. Initial
hepatocyte death triggers inflammation,
fibrosis, and late onset carcinogenesis,pointing to the crucial role of CYLD in the control of hepatocyte
homeostasis. Phenotypic and molecular-level analyses of liver-
specific CYLD-deficient mice revealed at least three temporally
distinct events schematically presented in Figure 7E.
The first observable phenotypic change in CYLDLD/D livers is
spontaneous apoptosis of periportal hepatocytes (Figure 7E,
left panel). This coincides with spontaneous activation of TAK1
and JNK. The well-known proapototic function of sustained
JNK activation (Kamata et al., 2005; Sakurai et al., 2006;
Schwabe and Brenner, 2006; Hui et al., 2008) provides a mecha-
nistic explanation for the observed occurrence of cell death. JNK
is a downstream substrate of the TAK1-induced kinase cascade,
suggesting that the initial triggering event of cell death must be
the spontaneous hyperactivation of TAK1. In agreement with
this, periportally restricted apoptosis was not observed in




Figure 7. Hepatic Tumors Developed in
CYLDLD/D Mice Express Oncofetal and
Stem Cell-Specific Genes
(A–C) RT-qPCR assays in total liver RNA from
1-year-old CYLDLD/D mice and control littermates
(WT) with primers amplifying the mRNAs of cancer
and stem cell markers indicated at the bottom of
the graphs. Bars represent mean mRNA levels
normalized to GAPDH mRNA and SEM from
samples of four individual mice. The data are
presented either as a fold over wild-type values (A)
for Cyclin D1, CTGF, GPC-3, and CD133 mRNAs,
or as percent of the values obtained with embry-
onic day 18.5 (E18) mouse livers (B) for AFP, IGF2,
and H19 mRNAs or as a percent of the values
obtained with RNAs prepared from pluripotent
mouse embryonic stem cells (C) NANOG, SOX2,
and KLF4 mRNAs.
(D) Representative immunohistochemical staining
of liver sections of 1-year-old CYLDLD/D mice with
SOX2 and HNF4 antibodies.
(E) Schematic presentation of the temporal order
of molecular and phenotypic changes in liver-
specific CYLD-deficient mice.
See also Table S2 and Figure S6.
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CYLD Inactivation in LiverHow is TAK1 activated in the periportal hepatocytes of
CYLDLD/D mice without external administration of signaling
molecules? The most straightforward and simplest explanation
is that the lack of CYLD-mediated cleavage of polyubiquitin
chains increases K63-linked ubiquitination of TAK1, which stim-
ulates TAK1 enzymatic activity independently of receptor
signaling. An alternative, but conceptually related, mechanism
is also suggested by our finding that CYLD-deficient hepato-
cytes, due to lack of deubiquitination-mediated control, are
more sensitive to activate TAK1 in response to low amounts of
LPS. Mice that are not kept under germ-free conditions are
constantly challenged with small doses of lipopolysaccharide
(LPS) produced by the intestinal bacterial flora, which can reach
the liver via the portal tract and induce cytokine production by
resident Kupffer cells (Enomoto et al., 2002). Thus, due to sensi-
tization, hepatocytes in the periportal area of CYLDLD/D mice
may respond to the locally available low amounts of LPS by acti-
vating TAK1 via death receptor signaling. Supporting this
scenario is the time frame of apoptotic cell appearance: although
CYLD is lost from hepatocytes before birth, apoptotic cells are
first detected about 10 days after weaning (at P25), when the
physiological bacterial flora of the gut is fully formed. Interest-
ingly, CYLD is expressed at higher levels in periportal hepato-
cytes, compared to those in the pericentral area. We speculate
that this partial zonal expression pattern may reflect anCancer Cell 21, 738–7increased demand for CYLD-mediated
control in the periportal area to protect
hepatocytes from apoptosis induced by
locally accumulating death-signaling
molecules.
Following the initial apoptosis of peri-
portal hepatocytes in CYLDLD/D mice,
hepatic stellate cells and Kupffer cells
are activated, leading to progressivefibrosis, inflammation, and TNFR1 signaling-dependent propa-
gation of cell death into an expanded area of the liver (Figure 7E,
middle panel). Dying hepatocytes release various mediators that
induce transdifferentiation of hepatic stellate cells into
myofibroblasts, which proliferate and produce a network of
extracellular matrix, the hallmark of a fibrotic scar (Bataller and
Brenner, 2005; Friedman, 2008). The resulting fibrosis acts as
a precursor of cirrhosis during chronic liver damage-induced
inflammation, in which excessive extracellular matrix deposition
disrupts liver cytoarchitecture (Bataller and Brenner, 2005).
Similar to human fibrotic livers, hepatocyte death in CYLDLD/D
mice is also associated with Kupffer cell activation and invasion
of inflammatory cells parallel to stellate cell activation. Kupffer
cells are resident macrophages in the liver and produce various
inflammatory cytokines (Gao et al., 2008). In CYLDLD/D livers, the
proliferation of Kupffer cells and the infiltration of other CD45
positive inflammatory cells correlated with the gradual increase
of TNFamRNA and phospho-JNK levels. This provides a mech-
anistic clue for the observed expansion of hepatocyte death
toward the central vein areas, as locally elevated levels of
TNFa could induce apoptosis in neighboring cells via the
TNFR1-dependent signaling cascade. Evidence for this was
provided by experiments in mice lacking both CYLD and p55-
TNFR1. Apoptotic hepatocytes and fibrotic lesions in the double
knockout mice were limited to the periportal areas even after50, June 12, 2012 ª2012 Elsevier Inc. 747
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CYLD Inactivation in LiverP60, suggesting that TNFR1 is required for the propagation of
liver damage in CYLDLD/D mice.
We also noted that the expression of DR5 was highly
increased in CYLDLD/D mice at P60, suggesting that signaling
through DR5 may also contribute to the observed phenotype.
However, such an effect should involve cooperation with
TNFR-1, as the latter was absolutely required for the propaga-
tion and expansion of cell death in CYLD-deficient mice.
Of particular interest is the timing of NFkB activation in
CYLDLD/Dmice. As CYLD is known to act as a negative regulator
of NFkB activation, it was surprising that we could not detect
NFkB-p65 stimulation up until P45. The levels of activated
NFkB-p65 peaked at P60, when massive cell death and inflam-
mation was evident, but long after complete CYLD inactivation
(embryonic life) or the first detection of apoptotic hepatocytes
and TAK1 hyperactivation (P25). Although the mechanism
behind this phenomenon is not understood, it is possible
that the TAK1-NFkB activation cascade requires more robust
signals that are available only at P45–P60 in CYLDLD/D livers.
Thus, TAK1 activation does not always lead to NFkB induction.
A similar lack of correlation between TAK1 and NFkB activa-
tion has also been observed in LPS-stimulated bone marrow-
derived macrophages (Tseng et al., 2010). The observed
preferential induction and chronic persistence of TAK1-JNK
phosphorylation cascade over NFkB activation are in agreement
with the observed cell death phenotype at the ‘‘early’’ stage.
Induction of NFkB-p65 at later stages (at P60) cannot reverse
cell death progression, suggesting that the dominance of the
TAK1-JNK cascade, which persists for a long period of time,
disrupts the balance between death signaling and compensa-
tory survival pathways.
Loss of CYLD has been described in human hepatocellular
carcinomas (Hellerbrand et al., 2007). The large majority of
hepatocellular carcinomas are detected in patients with hepatic
fibrosis or cirrhosis (Okuda, 2000). They develop in a setting of
chronic hepatocyte injury and inflammation, similar to that
observed in CYLDLD/D mice. In accordance with the above,
we found that CYLDLD/D mice spontaneously developed
hepatocellular carcinoma at the age of 12 months, pointing
to a potential causative and mechanistic relationship between
CYLD expression and the development of HCC. The preceding
massive cell death and the late appearance of carcinoma in
CYLDLD/D mice suggests that, similar to other HCC models
generated by genetic ablation of NFkB regulators (Maeda
et al., 2005; Luedde et al., 2007; Inokuchi et al., 2010; Better-
mann et al., 2010), the mechanism of carcinogenesis involves
compensatory cell proliferation (Figure 7E, right panel). Of
interest is that the hepatocellular carcinoma in CYLDLD/D mice
associates with the reactivation of oncofetal hepatic genes
(AFP, H19, IGF2), with the expression of cancer stem cell
(CSC) related genes (GPC-3, CD133), and with genes involved
in maintenance of embryonic stem cells (NANOG, SOX2,
KLF4). Activation of these latter genes has been implicated in
highly aggressive epithelial tumors, with very poor prognosis
(Ben-Porath et al., 2008). The above features demonstrate
that tumors developing in CYLDLD/D livers highly resemble
human hepatocellular carcinomas, whose expression profiles
are enriched in stem cell traits (Marquardt et al., 2011). The
activation of the oncofetal and ‘‘stem cell signature’’ genes748 Cancer Cell 21, 738–750, June 12, 2012 ª2012 Elsevier Inc.may arise from the high degree of dedifferentiation of hepato-
cytes that enter the cell cycle via G0-G1 transition or from
the proliferation of resident hepatic ‘‘stem cells,’’ or both. The
available data do not allow discrimination between these
possibilities.
Compensatory cell growth could be initiated by ROS accumu-
lation-mediated activation of the oncogenic transcription factor
STAT3 (He et al., 2010). The high levels of STAT3 activation in
CYLDLD/D mice from P60 and onward and the correlation of
STAT3 activation with the levels of ROS accumulation provide
a strong indication for its involvement in the process.
Both NEMO and TAK1 are subject to negative regulation by
CYLD-mediated deubiquitination (Kovalenko et al., 2003; Reiley
et al., 2007). Thus, it was surprising to see that several of the
phenotypic characteristics CYLDLD/D mice resemble those re-
ported in liver-specific NEMO and TAK1-deficient mice (Luedde
et al., 2007; Inokuchi et al., 2010; Bettermann et al., 2010). The
similar phenotypic features include: hepatocyte death, fibrosis,
inflammation and cancer. The similarities between CYLDLD/D
and TAK1LD/Dmice are of particular concern, since TAK1 hyper-
activation represents the earliest triggering event in the patho-
genesis of liver damage observed in the CYLDLD/D mice.
While our analysis of TAK1LD/D mice confirmed the findings of
previous reports, it also revealed significant differences between
CYLDLD/D and TAK1LD/Dmice in terms of timing, localization, and
the severity of cell death, fibrosis, and cancer phenotypes.
TAK1LD/D mice, generated by crossing TAK1lox with ALFP-Cre
(this study and Bettermann et al., 2010), developed full-blown
HCC at 1.5 months of age, as opposed to CYLDLD/Dmice, which
develop cancer at 10–12 months of age. In contrast to the
massive hepatocyte death and liver fibrosis of CYLDLD/D mice,
TAK1-deficient livers display only a few TUNEL positive cells
and much milder fibrotic lesions. An additional significant differ-
ence between CYLDLD/D and TAK1LD/Dmice is the different local
distribution of apoptotic hepatocytes and fibrotic lesions. Hepa-
tocyte death and fibrosis are initially limited and later expand to
an extended periportal zone in CYLDLD/D mice, while in TAK1-
deficient mice, the small number of apoptotic cells and milder
fibrotic lesions are uniformly distributed between central vein
and portal vein areas.
Despite these qualitative and quantitative differences, the end
result of both constitutive activation or inactivation of TAK1 is
spontaneously developing inflammation and cancer. Thus, either
aberrant increase or decrease of TAK1 activity is detrimental to
hepatocyte function. Our results highlight the role of CYLD in
keeping TAK1 activity in equilibrium, protecting the liver from
spontaneous damage. Therefore, we propose that CYLD acts
as a master regulator of TAK1-induced signaling cascades and




CYLDloxp mice carrying floxed exon 9 alleles of CYLD have been described
previously (Trompouki et al., 2009). To obtain liver-specific inactivation of
CYLD, we crossed CYLDloxp mice with ALFP-Cre transgenic mice (Kellen-
donk et al., 2000). CYLDloxp littermates without Cre transgene were used
as wild-type controls. For the generation of conditional TAK1-deficient
mice, we crossed mice containing floxed TAK1 exon 2 allele (Eftychi et al.,
Cancer Cell
CYLD Inactivation in Liver2012) with ALFP-Cre transgenic mice. TNFR1/ mice have been described
previously (Rothe et al., 1993). All animals were in C57Bl6 background. Mice
were maintained in grouped cages in a temperature-controlled, specific-
pathogen-free facility on a 12-hr light/dark cycle and fed by a standard
chow diet (Altromin 1324; 19% protein, 5% fat) and water ad libitum. All
animal experiments were approved by the Prefecture of Attica and were per-
formed in accordance with the respective national and European Union
regulations.
Histological Analysis
Histological assays were performed in paraffin-embedded or frozen tissue
sections as described previously (Boulias et al., 2005; Kyrmizi et al., 2006).
Briefly, livers were dissected, fixed in 4% paraformaldehyde, and embedded
in paraffin. Liver sections (5–6 mm thick) were boiled in 10 mM Na-citrate for
20 min and, after washings with PBS, were blocked with normal goat serum
in PBS and used for staining with aSMA antibody. For immunohistochemistry
with all of the other antibodies, cryosections were used. Freshly isolated liver
tissues were embedded in optimal cutting temperature (OCT) embedding
medium without fixation and samples were frozen in liquid nitrogen. Frozen
sections were air-dried before fixation in 4% formaldehyde for 15 min at
room temperature. Blocking was performed in 1% BSA/0,1% Triton X-100
for 1 hr and then incubated with primary antibodies at room temperature
for 2 hr or at 4C overnight. After incubation with AlexaFluor 568, 555, or
488 (Molecular Probes) secondary antibodies for 1 hr at room temperature
and counterstaining with DAPI, fluorescence images were observed using
a Zeiss Axioscope 2 Plus microscope. Paraffin-embedded tissue sections
were used for staining with 0.1% Sirius red dissolved in saturated picric acid
or with hematoxylin and eosin (H&E). Sirius-red positive areas were quanti-
tated using NIH Image-J software. TUNEL assays were performed using the
Fluorescein cell death detection kit (Roche). To detect proliferating cells,
mice were injected intraperitonelly with 1 mg/kg 50-Bromo-20-deoxyuridine
(Sigma) twice, in 12-hr intervals. Incorporated BrdU was detected in cryosec-
tions using mouse monoclonal aBrdU antibody (Sigma).
Accumulation of reactive oxygen species (ROS) was measured by staining
frozen liver sections with 2 mM of 5-(and-6)-chloromethyl-20,70-dichlorodihy-
drofluorescein diacetate, acetyl ester (CM-H2DCFDA) for 30 min at 37
C.
Cell survival in primary hepatocyte cultures was evaluated by MTT
assays using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide,
as described previously (Kontaki and Talianidis, 2010).
Biochemical Analysis
Blood was collected and centrifuged at 1000 g for 10 min. Freshly isolated
supernatant plasma fractions were used for measuring alanine aminotrans-
ferase (ALT) activity with the Dyasis assay kit.
Preparation of nuclear and whole cell extracts, immunoprecipitations, and
western blot assays were performed as described (Tatarakis et al., 2008; Mar-
tinez-Jimenez et al., 2010; Kontaki and Talianidis, 2010). For electrophoretic
mobility shift assays, double-stranded oligonucleotide was radiolabeled by
filling in with Klenow enzyme in the presence of a32P-dCTP. The oligonucleo-
tide used represents an NFkB consensus sequence: sense: 50-GGG TTG AGG
GGA CTT TCC CAG G; antisense: 50-GGG CCT GGG AAA CTC CCC TCA A.
Binding reactions were performed in 15 ml volume containing 20 mM HEPES
pH 7.9, 50 mM KCl, 2 mM MgCl2, 4 mM spermidine, 0.02 mM Zn-acetate,
0.1 mg/ml bovine serum albumin, 10% glycerol, 0.5 mM dithiotreitol, 2 mg
poly (dI-dC), and 5 mg nuclear extracts. After incubation in ice for 30 min, the
protein/DNA complexes were resolved in 5% native polyacrylamide gels and
visualized by autoradiography.
RNA Analysis
Total RNA was prepared by the Trizol extraction. After digestion with DNase I,
1 mg of total RNAwas used for first strand cDNA synthesis usingMMLV reverse
transcriptase. Quantitative PCR analyses were carried out in CHROMO4 Real
time PCR detection system by using SYBR Green reagent, as described
before (Kyrmizi et al., 2006). The nucleotide sequences of primer sets are
shown in Supplementary Information. For global gene expression, profiling
total RNAs from the whole livers of 1-year-old CYLDLD/D mice were analyzed
using Affimetrix GeneChIP Exon 1.0 ST Arrays, as described previously (Tatar-
akis et al., 2008).ACCESSION NUMBERS
Expression profiling and aCGH data were deposited to ArrayExpress under
accession numbers E-MEXP-3478 and E-MTAB-905, respectively.
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Supplemental Information includes six figures, two tables, and Supple-
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